Psilocybin mitigates the cognitive deficits observed in a rat model of Fragile X syndrome
Abstract
Rationale Fragile X syndrome (FXS) is the most common form of inherited intellectual disability (ID) and the leading monogenic cause of autism spectrum disorder (ASD). Serotonergic neurotransmission has a key role in the modulation of neuronal activity during development, and therefore, it has been hypothesized to be involved in ASD and co-occurring conditions including FXS. As serotonin is involved in synaptic remodeling and maturation, serotonergic insufficiency during childhood may have a compounding effect on brain patterning in neurodevelopmental disorders, manifesting as behavioral and emotional symptoms. Thus, compounds that stimulate serotonergic signaling such as psilocybin may offer promise as effective early interventions for developmental disorders such as ASD and FXS.Objectives The aim of the present study was to test whether different protocols of psilocybin administration mitigate cognitive deficits displayed by the recently validated Fmr1-Δ exon 8 rat model of ASD, which is also a model of FXS.Results Our results revealed that systemic and oral administration of psilocybin microdoses normalizes the aberrant cognitive performance displayed by adolescent Fmr1-Δ exon 8 rats in the short-term version of the novel object recognition test-a measure of exploratory behavior, perception, and recognition.Conclusions These data support the hypothesis that serotonin-modulating drugs such as psilocybin may be useful to ameliorate ASD-related cognitive deficits. Overall, this study provides evidence of the beneficial effects of different schedules of psilocybin treatment in mitigating the short-term cognitive deficit observed in a rat model of FXS.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Psilocybin may be effective in ameliorating ASD-related cognitive deficits.
“may be effective in ameliorating ASD-related cognitive deficits. 105”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [105]
A recent preclinical study in a rat model reported that serotonin-modulating drugs such as psilocybin may be effective in ameliorating ASD-related cognitive deficits.
“Additionally, a recent preclinical research involving a rat model reported that serotonin-modulating drugs such as psilocybin may be effective in ameliorating ASD-related cognitive deficits. 105”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [105]
Cites
Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000412 · Cited by 7,300 · see citing works
Lai, M.-C., Lombardo, M. V., & Baron-Cohen, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61539-1 · Cited by 2,371 · see citing works
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698 · see citing works
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301 · see citing works
Hollocks, M. J., Lerh, J. W., Magiati, I., Meiser-Stedman, R., & Brugha, T. S. (2019) · Psychological Medicine · doi:10.1017/s0033291718002283 · Cited by 988 · see citing works
Hagerman, R. J., Berry-Kravis, E., Hazlett, H. C., Bailey, D. B., Moine, H., Kooy, R. F., Tassone, F., Gantois, I., Sonenberg, N., Mandel, J. L., et al. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.65 · Cited by 838 · see citing works
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Vollenweider, F. X., & Kometer, M. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2884 · Cited by 723 · see citing works
Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex <i>in vivo</i>
Shao, L.-X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., & Kwan, A. C. (2021) · doi:10.1101/2021.02.17.431629 · Cited by 628 · cited 1× · see citing works
“Based on previous evidence showing enduring effects of psychedelics (Calder and Hasler 2022; Horsley et al. 2018; Martin et al. 2014; Shao et al. 2021), it is tempting to speculate that the ability of psilocybin microdoses to mitigate the short-term memory deficits displayed by Fmr1-Δexon 8 rats in the novel object re…”
Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
Shao, L.-X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., & Kwan, A. C. (2021) · Neuron · doi:10.1016/j.neuron.2021.06.008 · Cited by 626 · see citing works
Advances in the Treatment of Fragile X Syndrome
Hagerman, R. J., Berry-Kravis, E., Kaufmann, W. E., Ono, M. Y., Tartaglia, N., Lachiewicz, A., Kronk, R., Delahunty, C., Hessl, D., Visootsak, J., et al. (2009) · Pediatrics · doi:10.1542/peds.2008-0317 · Cited by 596 · see citing works
The serotonin system in autism spectrum disorder: From biomarker to animal models
Muller, C. L., Anacker, A. M. J., & Veenstra-VanderWeele, J. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2015.11.010 · Cited by 531 · see citing works
The translation of translational control by FMRP: therapeutic targets for FXS
Darnell, J. C., & Klann, E. (2013) · Nature Neuroscience · doi:10.1038/nn.3379 · Cited by 491 · see citing works
The pharmacology of psilocybin
Passie, T., Seifert, J., Schneider, U., & Emrich, H. M. (2002) · Addiction Biology · doi:10.1080/1355621021000005937 · Cited by 465 · cited 1× · see citing works
“As psilocybin is best-known to stimulate 5HT2A receptors, it is tempting to speculate that the benefits we obtained from psilocybin treatment may be via this mechanism (Gill et al. 2020; Lowe et al. 2021; Passie et al. 2002).”
BackgroundThe pharmacology of lysergic acid diethylamide: A review
Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00059.x · Cited by 455 · see citing works
Hasler, F., Grimberg, U., Benz, M. A., Huber, T., & Vollenweider, F. X. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1640-6 · Cited by 451 · see citing works
Lesch, K.-P., & Waider, J. (2012) · Neuron · doi:10.1016/j.neuron.2012.09.013 · Cited by 435 · see citing works
Autism Profiles of Males With Fragile X Syndrome
Harris, S. W., Hessl, D., Goodlin-Jones, B., Ferranti, J., Bacalman, S., Barbato, I., Tassone, F., Hagerman, P. J., Herman, K., & Hagerman, R. J. (2008) · American Journal on Mental Retardation · doi:10.1352/2008.113:427-438 · Cited by 396 · see citing works
The role of serotonin 5-HT2A receptors in memory and cognition
Zhang, G., & Stackman, R. W. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00225 · Cited by 386 · see citing works
Psychiatry & the psychedelic drugs. Past, present & future
Rucker, J. J. H., Iliff, J., & Nutt, D. J. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.12.040 · Cited by 343 · see citing works
A synaptic perspective of fragile X syndrome and autism spectrum Disorders.
Bagni, C., & Zukin, R. S. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.041 · Cited by 326 · see citing works
Psychedelic Psychiatry’s Brave New World
Nutt, D., Erritzøe, D., & Carhart-Harris, R. L. (2020) · Cell · doi:10.1016/j.cell.2020.03.020 · Cited by 322 · see citing works
Towards an understanding of psychedelic-induced neuroplasticity
Calder, A. E., & Hasler, G. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01389-z · Cited by 313 · see citing works
Fragile X-associated tremor/ataxia syndrome — features, mechanisms and management
Hagerman, R. J., & Hagerman, P. J. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.82 · Cited by 289 · see citing works
Gregorio, D. D., Aguilar‐Valles, A., Preller, K. H., Heifets, B. D., Hibicke, M., Mitchell, J., & Gobbi, G. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.1659-20.2020 · Cited by 261 · see citing works
Smigielski, L., Scheidegger, M., Kometer, M., & Vollenweider, F. X. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.04.009 · Cited by 248 · see citing works
The Therapeutic Potential of Psilocybin
Lowe, H. I. C., Toyang, N., Steele, B., Valentine, H., Grant, J. F., Ali, A., Ngwa, W., & Gordon, L. (2021) · Molecules · doi:10.3390/molecules26102948 · Cited by 206 · see citing works
Hibicke, M., Landry, A. N., Kramer, H. M., Talman, Z. K., & Nichols, C. D. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00493 · Cited by 205 · see citing works
Effect of Psilocybin on Empathy and Moral Decision-Making
Pokorny, T., Preller, K. H., Kometer, M., Dziobek, I., & Vollenweider, F. X. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx047 · Cited by 197 · see citing works
Psychedelics: Where we are now, why we got here, what we must do
Belouin, S. J., & Henningfield, J. E. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.02.018 · Cited by 188 · see citing works
Kuypers, K., Ng, L., Erritzoe, D., Knudsen, G., Nichols, C. D., Nichols, D. E., Pani, L., Soula, A., & Nutt, D. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119857204 · Cited by 188 · see citing works
Forstmann, M., Yudkin, D. A., Prosser, A. M. B., Heller, S. M., & Crockett, M. J. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1918477117 · Cited by 185 · see citing works
Autism spectrum disorder in fragile X syndrome: a longitudinal evaluation
Hernandez, R. N., Feinberg, R. L., Vaurio, R., Passanante, N. M., Thompson, R. E., & Kaufmann, W. E. (2009) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.32848 · Cited by 178 · see citing works
Decreased tryptophan metabolism in patients with autism spectrum disorders
Boccuto, L., Chen, C., Pittman, A. R., Skinner, C. D., McCartney, H., Jones, K. A., Bochner, B. R., Stevenson, R. E., & Schwartz, C. E. (2013) · Molecular Autism · doi:10.1186/2040-2392-4-16 · Cited by 171 · see citing works
Effects of <i>N</i>,<i>N</i>-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and Depression
Cameron, L. P., Benson, C. J., Dunlap, L. E., & Olson, D. E. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00134 · Cited by 171 · see citing works
Effects of serotonin 2A/1A receptor stimulation on social exclusion processing
Preller, K. H., Pokorny, T., Hock, A., Kraehenmann, R., Stämpfli, P., Seifritz, E., Scheidegger, M., & Vollenweider, F. X. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1524187113 · Cited by 169 · see citing works
Role of altered brain serotonin mechanisms in autism
Chugani, D. C. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001167 · Cited by 166 · see citing works
Behavioral neuroscience of autism
Takumi, T., Tamada, K., Hatanaka, F., Nakai, N., & Bolton, P. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.04.012 · Cited by 163 · see citing works
Vollenweider, F., Csomor, P., Knappe, B., Geyer, M., & Quednow, B. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301324 · Cited by 159 · see citing works
White, S. W., Simmons, G. L., Gotham, K. O., Conner, C. M., Smith, I. C., Beck, K. B., & Mazefsky, C. A. (2018) · Current Psychiatry Reports · doi:10.1007/s11920-018-0949-0 · Cited by 157 · see citing works
Melancia, F., Schiavi, S., Servadio, M., Cartocci, V., Campolongo, P., Palmery, M., Pallottini, V., & Trezza, V. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14435 · Cited by 145 · see citing works
Self-citationPositive expectations predict improved mental-health outcomes linked to psychedelic microdosing
Kaertner, L. S., Steinborn, M. B., Kettner, H., Spriggs, M. J., Roseman, L., Buchborn, T., Balaet, M., Timmermann, C., Erritzoe, D., & Carhart-Harris, R. L. (2021) · Scientific Reports · doi:10.1038/s41598-021-81446-7 · Cited by 145 · see citing works
How serotonin receptors regulate morphogenic signalling in neurons
Wirth, A., Holst, K., & Ponimaskin, E. G. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.03.007 · Cited by 122 · see citing works
Behavioral analysis of male and female Fmr1 knockout mice on C57BL/6 background
Ding, Q., Sethna, F., & Wang, H. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.05.046 · Cited by 121 · see citing works
Ventura, R., Pascucci, T., Catania, M. V., Musumeci, S. A., & Puglisi‐Allegra, S. (2004) · Behavioural Pharmacology · doi:10.1097/00008877-200409000-00018 · Cited by 121 · see citing works
Microdosing psychedelics: Motivations, subjective effects and harm reduction
Lea, T., Amada, N. M., Jungaberle, H., Schecke, H., & Klein, M. (2019) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2019.11.008 · Cited by 121 · see citing works
Multifarious Functions of the Fragile X Mental Retardation Protein
Davis, J. K., & Broadie, K. S. (2017) · Trends in Genetics · doi:10.1016/j.tig.2017.07.008 · Cited by 118 · see citing works
Tartaglione, A. M., Schiavi, S., Calamandrei, G., & Trezza, V. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.12.024 · Cited by 112 · see citing works
Self-citationTill, S. M., Asiminas, A., Jackson, A. D., Katsanevaki, D., Barnes, S. A., Osterweil, E. K., Bear, M. F., Chattarji, S., Wood, E. R., Wyllie, D. J. A., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv299 · Cited by 109 · see citing works
Hessl, D. R., Tassone, F., Cordeiro, L., Koldewyn, K., McCormick, C. E. B., Green, C. C., Wegelin, J. A., Yuhas, J. M., & Hagerman, R. J. (2007) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-007-0365-5 · Cited by 105 · see citing works
The fragile X syndrome: exploring its molecular basis and seeking a treatment
Bardoni, B., Davidovic, L., Bensaid, M., & Khandjian, É. W. (2006) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399406010751 · Cited by 100 · see citing works
Serotonin in autism and pediatric epilepsies
Chugani, D. C. (2004) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/mrdd.20021 · Cited by 93 · see citing works
Speranza, L., Labus, J., Volpicelli, F., Guseva, D., Lacivita, E., Leopoldo, M., Bellenchi, G. C., di Porzio, U., Bijata, M., Perrone‐Capano, C., et al. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.13962 · Cited by 91 · see citing works
Sex differences and serotonergic mechanisms in the behavioural effects of psilocin
Tylš, F., Páleníček, T., Kadeřábek, L., Fujáková-Lipski, M., Kubešová, A., & Horáček, J. (2015) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000198 · Cited by 86 · see citing works
The therapeutic potential of microdosing psychedelics in depression
Kuypers, K. P. C. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320950567 · Cited by 85 · see citing works
Schiavi, S., Iezzi, D., Manduca, A., Leone, S., Melancia, F., Carbone, C., Petrella, M., Mannaioni, G., Masi, A., & Trezza, V. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00479 · Cited by 84 · see citing works
Self-citationLoss of FMRP Impaired Hippocampal Long-Term Plasticity and Spatial Learning in Rats
Tian, Y., Yang, C., Shang, S., Cai, Y., Deng, X., Zhang, J., Shao, F., Zhu, D., Liu, Y., Chen, G., et al. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00269 · Cited by 82 · see citing works
Sakashita, Y., Abe, K., Katagiri, N., Kambe, T., Saitoh, T., Utsunomiya, I., Horiguchi, Y., & Taguchi, K. (2015) · Biological ^|^ Pharmaceutical Bulletin · doi:10.1248/bpb.b14-00315 · Cited by 81 · cited 1× · see citing works
“Studies with high doses of psilocin, an active metabolite of psilocybin, showed behavioral impairments in rats (Sakashita et al. 2015; Tyls et al. 2016), including worsened learning performance in the Morris Water Maze test (Rambousek et al.”
BackgroundBuchborn, T., Schröder, H., Höllt, V., & Grecksch, G. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114531666 · Cited by 72 · see citing works
Higgins, G. A., Carroll, N. K., Brown, M., MacMillan, C., Silenieks, L. B., Thevarkunnel, S., Izhakova, J., Magomedova, L., DeLannoy, I., & Sellers, E. M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.640241 · Cited by 70 · see citing works
Chronic LSD alters gene expression profiles in the mPFC relevant to schizophrenia
Martin, D. A., Marona-Lewicka, D., Nichols, D. E., & Nichols, C. D. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.03.013 · Cited by 67 · see citing works
Manduca, A., Bara, A., Larrieu, T., Lassalle, O., Joffre, C., Layé, S., & Manzoni, O. J. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.3516-16.2017 · Cited by 63 · see citing works
Self-citationThe emerging role of psilocybin and MDMA in the treatment of mental illness
Gill, H., Gill, B., Chen-Li, D. C. J., El‐Halabi, S., Rodrigues, N. B., Cha, D. S., Lipsitz, O., Lee, Y. L., Rosenblat, J. D., Majeed, A., et al. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1826931 · Cited by 62 · see citing works
Oña, G., & Bouso, J. C. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.09.035 · Cited by 58 · see citing works
Costa, L., Sardone, L. M., Lacivita, E., Leopoldo, M., & Ciranna, L. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00065 · Cited by 57 · see citing works
Lithium treatment alleviates impaired cognition in a mouse model of fragile X syndrome
King, M. K., & Jope, R. S. (2013) · Genes Brain & Behavior · doi:10.1111/gbb.12071 · Cited by 57 · see citing works
Servadio, M., Manduca, A., Melancia, F., Leboffe, L., Schiavi, S., Campolongo, P., Palmery, M., Ascenzi, P., di Masi, A., & Trezza, V. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.11.014 · Cited by 56 · see citing works
Self-citationThe Effect of Psilocin on Memory Acquisition, Retrieval, and Consolidation in the Rat
Rambousek, L., Páleníček, T., Valeš, K., & Stuchlı́k, A. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00180 · Cited by 55 · see citing works
Serotonin Metabolism and Other Biochemical Parameters in Infantile Autism
Launay, J., Ferrari, P., Haimart, M., et al. (2008) · Neuropsychobiology · doi:10.1159/000118465 · Cited by 52 · see citing works
Horsley, R. R., Páleníček, T., Kolin, J., & Valeš, K. (2018) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000394 · Cited by 52 · see citing works
Schill, Y., Bijata, M., Kopach, O., Cherkas, V., Galil, D. A., Böhm, K., Schwab, M. H., Matsuda, M., Compan, V., Basu, S., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-0791-x · Cited by 50 · see citing works
Costa, L., Sardone, L. M., Bonaccorso, C. M., D’Antoni, S., Spatuzza, M., Gulisano, W., Tropea, M. R., Puzzo, D., Leopoldo, M., Lacivita, E., et al. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00353 · Cited by 49 · see citing works
Evaluating the Potential Use of Serotonergic Psychedelics in Autism Spectrum Disorder
Markopoulos, A., Inserra, A., De Gregorio, D., & Gobbi, G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.749068 · Cited by 46 · see citing works
Serotonin dysregulation in Fragile X Syndrome: implications for treatment
Hanson, A. C., & Hagerman, R. J. (2014) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2014.01027 · Cited by 40 · see citing works
Borsoï, M., Manduca, A., Bara, A., Lassalle, O., Pélissier‐Alicot, A., & Manzoni, O. J. (2019) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2019.00023 · Cited by 39 · see citing works
Self-citationSchiavi, S., Carbone, E., Melancia, F., Buzzelli, V., Manduca, A., Campolongo, P., Pallottini, V., & Trezza, V. (2022) · Nutritional Neuroscience · doi:10.1080/1028415x.2020.1819107 · Cited by 34 · see citing works
Self-citationModelling fragile X syndrome in the laboratory setting: A behavioral perspective
Melancia, F., & Trezza, V. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.04.042 · Cited by 29 · see citing works
Self-citationGolden, C. E. M., Breen, M. S., Koro, L., Sonar, S., Niblo, K., Browne, A., Burlant, N., Di Marino, D., De Rubeis, S., Baxter, M. G., et al. (2019) · Cerebral Cortex · doi:10.1093/cercor/bhz029 · Cited by 29 · see citing works
Schiavi, S., Manduca, A., Carbone, E., Buzzelli, V., Rava, A., Feo, A., Ascone, F., Morena, M., Campolongo, P., Hill, M. N., et al. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01454-7 · Cited by 26 · see citing works
Self-citationFragile X-Associated Tremor/Ataxia Syndrome (FXTAS)
Zafarullah, M., & Tassone, F. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9080-1_15 · Cited by 15 · see citing works
Psilocybin rescues sociability deficits in an animal model of autismPreprint
Mollinedo-Gajate, I., Song, C., Sintes, M., Whelan, T. P., Soula, A., Selimbeyoglu, A., Hurley, S., & Knöpfel, T. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.09.289348 · Cited by 6 · see citing works
Lidow (1998) · doi:10.1002/(sici)1098-2396(199801)28:1
Flagged first, then by citations
Cited by
Sorted by citations
Scala, M., Fabbri, C., Fusar-Poli, P., Di Lorenzo, G., Ferrara, M., Amerio, A., Fusar-Poli, L., Pichiecchio, A., Asteggiano, C., Menchetti, M., et al. (2024) · CNS Spectrums · doi:10.1017/s1092852924002268 · Cited by 9 · see citing works
- Authors
- Buzzelli, V., Carbone, E., Manduca, A., Schiavi, S., Feo, A., Perederiy, J. V., Ambert, K. H., Hausman, M., & Trezza, V.
- Affiliations
- Roma Tre University (IT)
- Corresponding author
- Trezza, Viviana
- Venue
- Psychopharmacology
- Published
- 2022-12-05
- Volume
- 240
- Issue
- 1
- Pages
- 137-147
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W4310700160
- Cited by
- 22
- References
- 82
- Citations by year
- 2026: 6 · 2025: 1 · 2024: 7 · 2023: 8
- FWCI
- 2.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Iris (Roma Tre University) (submittedVersion)
- Funders
- Ministero dell’Istruzione, dell’Università e della Ricerca (2017SXEXT5)
- Regione Lazio (“Gruppi di ricerca 2020” grant # PROT. A0375-2020-36550)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Keywords
- psilocybin, fragile X syndrome, autism spectrum disorder, cognitive impairment, novel object recognition, serotonergic neurotransmission, microdosing, treatment schedule, intellectual disability, neurodevelopmental disorders
- MeSH terms
- Autism Spectrum Disorder, Animals, Cognition, Fragile X Syndrome, Psilocybin, Serotonin, Rats, Fragile X Mental Retardation Protein, Fragile X Messenger Ribonucleoprotein 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
